Real World Evidence – Data for health

Real World Evidence (RWE) provides you with strategic support throughout the entire lifespan of medical products. With our solid expertise in RWE studies, we offer valuable information and services for successful progress from clinical phases to the post-marketing phase IV.

Oriola provides these services:

  • Our team of experienced specialists offers a wide range of services, including feasibility studies, patient surveys, drug utilization studies, and phase IV studies.
  • Leverage our unique digital platform for patient-reported outcomes, ensuring GDPR-compliant data usage and transparent medical research.
  • Combine Real World Data (RWD) from national registers and hospital data lakes with Patient Reported Outcomes (PRO) for a comprehensive view.
  • Gain insights into disease burden by incorporating patients' perspectives with national health register data.
  • We offer market research, landscape analyses, and data for health economic models to support market entry and pricing board decisions.

Nordic countries offer excellent conditions for register studies

Nordic countries provide ideal conditions for register studies, with similar laws, electronic data collection, and nation-wide cohort creation. 

Way to success: RWD + PRO = RWE

  • RWD (Real World Data): Collected from national registers, hospital data-lakes including various electronic medical records, and private healthcare providers.
  • PRO (Patient Reported Outcomes): Data collected through Oriola’s Research Pharmacy Network (around 150 active pharmacies in Finland), patient organisations and private healthcare providers.
  • RWD + PRO = RWE: Comprehensive picture of disease burden by combining patients’ perspective to national health register data

Contact us

Do not hesitate to contact us – we are ready to plan a tailored project just for your needs!

Tuire Prami

Tuire Prami

Real World Evidence Team Lead +358 50 546 8459 tuire.prami@oriola.com

Interested in our other services?

You find them and relevant contact details here.

A selection of our publications

Medication Counselling on Unlicensed Medicines Should Be Improved (2024) Nationwide Cohort Study on Healthcare Resource Use and Costs due to Multiple Myeloma in Finland (2024) Prevalence of cystic fibrosis and healthcare resource use in Finland (2024) New Legislation Allows Substitution of Biological Medicines in Pharmacies - Recent Patient Survey Reveals Obstacles for the Aims to Reduced Health Care Costs (2024) Recent trends in incidence, survival and treatment of multiple myeloma in Finland – a nationwide cohort study (2023) Opioid treatment barriers in high-risk users in Finland - A survey (2023) A registry study on treatment and disease control of type 2 diabetes patients in Finland (at the end of the article there is an English summary) DISCO patient survey: Room for improvement in type 2 diabetes treatment plans and targeting (2023) (at the end of the article there is an English summary) Real-world registry-based study on apremilast use in psoriasis and psoriatic arthritis in Finland (2023) Patient utilization survey of mirabegron prescribed for overactive bladder (2019) Attitudes and actions: A survey to assess statin use among Finnish patients with increased risk for cardiovascular events (2017) Characteristics of first-time varenicline users - A cross-sectional study in Finnish quitters (2016) A survey on the medication adherence to methotrexate among rheumatoid arthritis patients treated with self-administered biologic drugs (2016)

Read also

10.01.2024 | News

Apteekkisydän pharmacy in Naantali recognised as the Research Pharmacy of the Year 2023

Information acquired from patients is increasingly used in pharmacotherapy decision making to assess for example the effectiveness and cost effectiveness of treatment. Apteekkisydän pharmacy in Naantali gained the Research Pharmacy of the Year 2023 recognition from its active participation in conducting patient surveys. Research pharmacies in Finland are an internationally unique concept for collecting patients’ own experiences from their treatment.

14.11.2023 | News

First time in the Finnish pharmaceutical market? Join our webinar!

Successfully introducing a new medicinal product to the Finnish market requires expertise. Whether you are planning to enter the Finnish market or have already launched but feel that you still lack country-specific knowledge, this training is designed for you.

28.09.2023 | News

Recent study: The number of working-age adults with diabetes is growing, and their disease control is worse than average

A recent registry study investigated the treatment and disease control of Finnish type 2 diabetes patients. The results of the study are noteworthy: the prevalence of the disease is increasing rapidly, and the working-age population has poorer-than-average disease control compared with other age groups. This is a worrying trend for both public health and the quality of life of the affected.